1. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
    K.-S.N. Atretkhany et al, 2016, Pharmacology & Therapeutics CrossRef
  2. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
    Xiao-Ming Jiang et al, 2017, Acta Pharmacol Sin CrossRef
  3. A nonimmune function of T cells in promoting lung tumor progression
    Jesse A. Green et al, 2017, J. Exp. Med. CrossRef
  4. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
    K Kondo et al, 2017, Leukemia CrossRef
  5. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Ross A Soo et al, 2018, Lung Cancer CrossRef
  6. PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
    David F. Heigener et al, 2017, Journal of Thoracic Oncology CrossRef
  7. Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy
    Xianda Zhao et al, 2018, Pharmacology & Therapeutics CrossRef
  8. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
    Xue Li et al, 2018, Cancer Letters CrossRef
  9. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
    LiJun Xu et al, 2018, Mol Oncol CrossRef
  10. Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma
    Xing Song et al, 2018, EBioMedicine CrossRef
  11. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer
    Shuo Wang et al, 2018, FEBS Lett CrossRef
  12. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
    Daniel E Johnson et al, 2018, Nat Rev Clin Oncol CrossRef
  13. Regulation and Function of the PD-L1 Checkpoint.
    Chong Sun et al, 2018, Immunity CrossRef
  14. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma
    Ping-Chih Hsu et al, 2018, J Cell Mol Med CrossRef
  15. Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma
    Yiwei Liu et al, 2018, Clinical Lung Cancer CrossRef
  16. Molecular cross-talk of IL-6 in tumors and new progress in combined therapy
    Zuoqing Song et al, 2018, Thorac Cancer CrossRef
  17. STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
    Ilaria Attili et al, 2018, Ther Adv Med Oncol CrossRef
  18. Investigation of miR-136-5p key target genes and pathways in lung squamous cell cancer based on TCGA database and bioinformatics analysis
    Zu-cheng Xie et al, 2018, Pathology - Research and Practice CrossRef
  19. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer
    Kriti Ray et al, 2018, Cytokine & Growth Factor Reviews CrossRef
  20. The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer
    Dongfang Tang et al, 2018, J Cell Mol Med CrossRef
  21. “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
    Emira Bousoik et al, 2018, Front. Oncol. CrossRef
  22. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers
    Chun-Chia Cheng et al, 2018, Molecular Carcinogenesis CrossRef
  23. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis.
    Li Sun et al, 2018, Cell Death Dis CrossRef
  24. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia
    Shahrzad Jalali et al, 2018, Blood Adv CrossRef
  25. Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer
    Spiros Vlahopoulos et al, 2018, Pharmacology & Therapeutics CrossRef
  26. Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer.
    Spiros Vlahopoulos et al, 2019, Pharmacol Ther CrossRef
  27. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
    Jinfang Zhang et al, 2018, Trends Biochem Sci CrossRef
  28. MiR-940 Promotes the Proliferation and Migration of Gastric Cancer Cells through Up-regulation of Programmed Death Ligand-1 Expression
    Yibo Fan et al, 2018, Experimental Cell Research CrossRef
  29. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
    Xianjie Jiang et al, 2019, Mol Cancer CrossRef
  30. Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
    Cheng Xu et al, 2018, Chinese Medical Journal CrossRef
  31. Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.
    Nobuhide Higashino et al, 2019, Lab Invest CrossRef
  32. Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells
    Wenyi Gu et al, 2019, Clin Exp Pharmacol Physiol CrossRef
  33. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling
    Ming-Shao Tsai et al, 2019, Oral Oncology CrossRef
  34. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
    Mingjing Shen et al, 2019, J Exp Clin Cancer Res CrossRef
  35. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
    Miyuki Sato et al, 2019, PLoS One CrossRef
  36. CSTP1 inhibits IL-6 expression through targeting Akt/FoxO3a signaling pathway in bladder cancer cells
    Dexiang Zhuo et al, 2019, Experimental Cell Research CrossRef
  37. Nimotuzuma restrains proliferation and induces apoptosis in human osteosarcoma cells by regulation of EGFR/PI3K/AKT signal pathway
    Meihan Liu et al, 2019, J Cell Physiol CrossRef
  38. Exploring Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells
    Tiepeng Li et al, 2019, Biochemistry CrossRef
  39. ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer
    Iris C. Salaroglio et al, 2019, IJMS CrossRef
  40. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
    Xiangfeng Shen et al, 2019, Front. Immunol. CrossRef
  41. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging
    Dan Li et al, 2019, Mol. Pharmaceutics CrossRef
  42. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
    Yang Zhang et al, 2019, Respir Res CrossRef
  43. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Ping-Chih Hsu et al, 2019, IJMS CrossRef
  44. Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions
    Shohreh Azadi et al, 2019, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research CrossRef
  45. Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors
    Sahyun Pak et al, 2019, J Cancer Res Clin Oncol CrossRef
  46. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
    Yilun Wu et al, 2019, Front. Immunol. CrossRef
  47. STAT3, a Master Regulator of Anti-Tumor Immune Response
    null Rébé et al, 2019, Cancers CrossRef
  48. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
    Anqi Lin et al, 2019, Mol Cancer CrossRef
  49. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils
    Anquan Shang et al, 2019, J Exp Clin Cancer Res CrossRef
  50. Interleukin‐17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma
    Aeri Aotsuka et al, 2019, Cancer Sci CrossRef
  51. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma
    Byung Soo Lee et al, 2017, Biochemical and Biophysical Research Communications CrossRef
  52. The potential and controversy of targeting STAT family members in cancer.
    Yannick Verhoeven et al, 2020, Semin Cancer Biol CrossRef
  53. STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
    null Zerdes et al, 2019, Cancers CrossRef
  54. PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model
    Suming Shi et al, 2019, Cephalalgia CrossRef
  55. Mechanisms Controlling PD-L1 Expression in Cancer.
    Jong-Ho Cha et al, 2019, Mol Cell CrossRef
  56. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment
    Li Yang et al, 2019, J Hematol Oncol CrossRef
  57. The α9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration
    Hai Duong Nguyen et al, 2019, Cancers CrossRef
  58. Oncogenic signaling pathways associated with immune evasion and the resistance to immune checkpoint inhibitors in cancer
    Yoshie Kobayashi et al, 2019, Seminars in Cancer Biology CrossRef
  59. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer
    Katsuhiro Yoshimura et al, 2020, Lung Cancer CrossRef
  60. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells
    Junyu Xiang et al, 2019, Gastroenterology CrossRef
  61. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Shuling Zhang et al, 2020, International Immunopharmacology CrossRef
  62. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer
    Zhu Lingling et al, 2020, Pathology - Research and Practice CrossRef
  63. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB.
    Wen Liu et al, 2020, Cell Prolif CrossRef
  64. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
    Yiran Cai et al, 2020, BMC Cancer CrossRef
  65. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Hiro Sato et al, 2020, Int J Clin Oncol CrossRef
  66. Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
    Tamio Okimoto et al, 2020, Cancer Sci CrossRef
  67. STAT3: Versatile Functions in Non-Small Cell Lung Cancer
    Julian Mohrherr et al, 2020, Cancers CrossRef
  68. Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer
    Tae-Jung Kim et al, 2017, Oncotarget CrossRef
  69. Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
    Zengzhi Lian et al, 2020, Thorac Cancer CrossRef
  70. Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Rui Jin et al, 2020, Ther Adv Med Oncol CrossRef
  71. Tobacco extracts promote PD‐L1 expression and enhance malignant biological differences via mTOR in gefitinib‐resistant cell lines
    Fengqi Xiao et al, 2020, Thorac Cancer CrossRef
  72. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers
    Yating Tang et al, 2018, Oncol Lett CrossRef
  73. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.
    Lan Zhang et al, 2018, Mol Med Rep CrossRef
  74. Positive PD‑L1 expression is predictive for patients with advanced EGFR wild‑type non‑small cell lung cancer treated with gemcitabine and cisplatin
    Yajuan Qiu et al, 2019, Oncol Lett CrossRef
  75. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
    Tung-Yung Huang et al, 2020, Cells CrossRef
  76. Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors
    Kathrina L. Marcelo-Lewis et al, 2020 CrossRef
  77. Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
    Julia Delahousse et al, 2020, J Immunother Cancer CrossRef
  78. Mechanisms of Cancer Resistance to Immunotherapy
    Rilan Bai et al, 2020, Front. Oncol. CrossRef
  79. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
    Chen Zhu et al, 2020, Front. Immunol. CrossRef
  80. Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
    Yijun Jia et al, 2020, Front. Oncol. CrossRef
  81. null
    Saul Suster et al, 2017 CrossRef
  82. Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade
    Xinrui Zhao et al, 2020, Cancers CrossRef
  83. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
    Elena Shklovskaya et al, 2020, IJMS CrossRef
  84. Emerging role of tumor cell plasticity in modifying therapeutic response.
    Siyuan Qin et al, 2020, Signal Transduct Target Ther CrossRef
  85. The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
    Giuseppe Lamberti et al, 2020, Cancers CrossRef
  86. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway
    Wenwen Du et al, 2020, Cell Death Differ CrossRef
  87. Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer.
    Erwin Tomasich et al, 2021, Transl Res CrossRef
  88. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
    Muhammad Khan et al, 2020, Front. Immunol. CrossRef
  89. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
    Liangliang Cai et al, 2020, Front. Immunol. CrossRef
  90. Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals
    Dae Young Lee et al, 2020, Seminars in Cancer Biology CrossRef
  91. Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression
    Abilasha G. Jayathilake et al, 2020, BMC Complement Med Ther CrossRef
  92. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
    Yulong Fu et al, 2020, J Hematol Oncol CrossRef
  93. Genomic Mutations of Primary and Metastatic Lung Adenocarcinoma in Chinese Patients
    Xinyu Chen et al, 2020, Journal of Oncology CrossRef
  94. Immunomodulation by targeted anticancer agents
    Giulia Petroni et al, 2020, Cancer Cell CrossRef
  95. Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
    Florida Voli et al, 2020, Cancer Res CrossRef
  96. IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung
    Bo Jing et al, 2020, Cancer Res CrossRef
  97. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
    Jiayi Yu et al, 2019, Clin Cancer Res CrossRef
  98. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
    Jung-Mao Hsu et al, 2018, Cancer Res CrossRef
  99. Antitumour immunity regulated by aberrant ERBB family signalling
    Shogo Kumagai et al, 2021, Nat Rev Cancer CrossRef
  100. Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment.
    Yongbo Yu et al, 2021, Cell Death Discov CrossRef
  101. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer
    Juan Zhou et al, 2021, Lung Cancer CrossRef
  102. IL-6 in inflammation, autoimmunity and cancer.
    Toshio Hirano, 2021, Int Immunol CrossRef
  103. The PI3K /Akt/ mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies
    Nader Akbari Dilmaghani et al, 2021, IUBMB Life CrossRef
  104. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
    Jingjing Qu et al, 2021, Ther Adv Med Oncol CrossRef
  105. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
    Yannick Verhoeven et al, 2021, IJMS CrossRef
  106. EGFR and PDL1: A Match (Not) Made in Heaven—A Real-World Retrospective Analysis of PDL1 Expression in EGFR-Mutated NSCLC
    Ullas Batra et al, 2021, Adv Ther CrossRef
  107. PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
    Min Luo et al, 2021, Acta Pharmaceutica Sinica B CrossRef
  108. Antitumor Effects of Ursolic Acid through Mediating the Inhibition of STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer Cells.
    Dong Young Kang et al, 2021, Biomedicines CrossRef
  109. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
    Youqian Wu et al, 2021, Nat Commun CrossRef
  110. The intersection of COVID-19 and cancer: signaling pathways and treatment implications
    Zhi Zong et al, 2021, Mol Cancer CrossRef
  111. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
    Kenneth K. W. To et al, 2021, Front. Oncol. CrossRef
  112. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
    Meng Qiao et al, 2021, Journal of Thoracic Oncology CrossRef
  113. ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer
    Ah-Rong Nam et al, 2021, Cancer Letters CrossRef
  114. PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway
    Shilong Zhao et al, 2021, Inflammation CrossRef
  115. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
    Jan Budczies et al, 2021, Cancer Immunol Immunother CrossRef
  116. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
    Tania Crombet Ramos et al, 2021, Front. Oncol. CrossRef
  117. Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy
    Quan Cheng et al, 2021, Front. Cell Dev. Biol. CrossRef
  118. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1
    Noreen Nog‐Qin Chui et al, 2021, Hepatol Commun CrossRef
  119. PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells
    Hongmei Zhang et al, 2021, Cellular Signalling CrossRef
  120. The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
    Christophe Glorieux et al, 2021, Cancers CrossRef
  121. Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor
    Siddharth Sourabh Sahu et al, 2021, ACS Appl. Mater. Interfaces CrossRef
  122. Autophagy controls programmed death‑ligand 1 expression on cancer cells (Review)
    Lijuan Gao et al, 2021, Biomed Rep CrossRef
  123. Abrogation of STAT3 activation cascade by Ginkgolide C mitigates tumourigenesis in lung cancer preclinical model
    Min Hee Yang et al, 2021 CrossRef
  124. Development and Validation of an IL6/JAK/STAT3-Related Gene Signature to Predict Overall Survival in Clear Cell Renal Cell Carcinoma
    Chuanchuan Zhan et al, 2021, Front. Cell Dev. Biol. CrossRef
  125. Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
    Xiaoxin Ren et al, 2021, Genes & Diseases CrossRef
  126. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
    Guoqing Qian et al, 2021, Mol Cancer Res CrossRef
  127. Antibodies to EGF Receptor Family Members Can Upregulate Tumor Immunity
    Min Dai et al, 2021 CrossRef
  128. Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy
    Shubhangi Gavali et al, 2021, IJMS CrossRef
  129. Differential expression of long non-coding RNAs as diagnostic markers for lung cancer and other malignant tumors
    Li Li et al, 2021, Aging CrossRef
  130. The genomic landscape of lung adenocarcinoma—insights towards personalized medicine
    Ovleen Kour et al, 2021, Proc.Indian Natl. Sci. Acad. CrossRef
  131. Potential biomarkers and resistance mechanisms of atezolizumab in a patient with lung squamous cell carcinoma
    Kangqi Ren et al, 2021, Immunotherapy CrossRef
  132. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
    Nathaniel Wiest et al, 2021, Front. Oncol. CrossRef
  133. MicroRNA-374a Promotes Hepatocellular Carcinoma Cell Proliferation by Targeting Mitogen-Inducible Gene 6 (MIG-6)
    Hui Li et al, 2018, oncol res CrossRef
  134. Multicellular Effects of STAT3 in Non-Small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
    Sagun Parakh et al, 2021, Cancers CrossRef
  135. What is the current role of immunotherapy in EGFR mutant advanced NSCLC?
    Maria A Velez et al, 2021, Lung Cancer CrossRef
  136. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
    Ichidai Tanaka et al, 2021, IJMS CrossRef
  137. Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway
    Yao Lu et al, 2021, Front. Oncol. CrossRef
  138. null
    Mohamad A. Salkeni et al, 2021 CrossRef
  139. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
    Reza Elahi et al, 2022, International Immunopharmacology CrossRef
  140. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer
    Kang Chen et al, 2022, Front. Oncol. CrossRef
  141. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
    Hirohito Yamaguchi et al, 2022, Nat Rev Clin Oncol CrossRef
  142. Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment
    Priyanka Singh et al, 2022 CrossRef
  143. Zinc Status Impacts the Epidermal Growth Factor Receptor and Downstream Protein Expression in A549 Cells
    Emily Scheiermann et al, 2022, IJMS CrossRef
  144. The Lymph Node Microenvironment May Invigorate Cancer Cells With Enhanced Metastatic Capacities
    Tianhang Li et al, 2022, Front. Oncol. CrossRef
  145. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
    Paula Dobosz et al, 2022, IJMS CrossRef
  146. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
    Mengling Wu et al, 2022, J Hematol Oncol CrossRef
  147. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
    Giulia Petroni et al, 2022, Nat Rev Drug Discov CrossRef
  148. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
    Robert J Motzer et al, 2022, J Immunother Cancer CrossRef
  149. Immunomodulatory role of thrombin in cancer progression
    Eric T. Alexander et al, 2022, Molecular Carcinogenesis CrossRef
  150. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer
    Yan Chen et al, 2022, Future Oncology CrossRef
  151. Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non‑small cell lung cancer (Review)
    Li Jiang et al, 2022, Oncol Lett CrossRef
  152. Targeting protein kinases benefits cancer immunotherapy
    Zhengkun Zhang et al, 2022, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  153. TMEM16A as a potential treatment target for head and neck cancer
    Kohei Okuyama et al, 2022, J Exp Clin Cancer Res CrossRef
  154. Identification of Biomarkers Associated With CD8+ T Cells in Coronary Artery Disease and Their Pan-Cancer Analysis
    Shijian Zhao et al, 2022, Front. Immunol. CrossRef
  155. Polysaccharide Peptide Induced Colorectal Cancer Cells Apoptosis by Down-Regulating EGFR and PD-L1 Expression
    Lin Jian et al, 2022, Iran J Pharm Res CrossRef
  156. EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma
    Wenyue Zhao et al, 2022, International Immunopharmacology CrossRef
  157. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
    Thomas Denize et al, 2022 CrossRef
  158. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
    James J. Kang et al, 2022, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  159. Non-small-cell lung cancer-associated gene mutations and inhibitors
    Ashwini Kumar et al, 2022, Advances in Cancer Biology - Metastasis CrossRef
  160. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
    Kun Pang et al, 2022, Drug Resistance Updates CrossRef
  161. A cohort study using IL-6/Stat3 activity and PD-1/PD-L1 expression to predict five-year survival for patients after gastric cancer resection
    Xiao Ning Li et al, 2022, PLoS ONE CrossRef
  162. Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model
    Chih-Hung Guo et al, 2022, Marine Drugs CrossRef
  163. Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
    Kostas A. Papavassiliou et al, 2023, Cancers CrossRef
  164. Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)
    Jiao Deng et al, 2022, Oncol Lett CrossRef
  165. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
    Itziar Otano et al, 2023, Nat Rev Clin Oncol CrossRef
  166. Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
    Chen Jie et al, 2023, Front. Immunol. CrossRef
  167. null
    Mei Lan Tan et al, 2023 CrossRef
  168. MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation
    Yuan Wang et al, 2023, Cell Discov CrossRef
  169. null
    David Terrero et al, 2023 CrossRef
  170. Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors
    Shi-Yong Sun, 2023, Chinese Medical Journal - Pulmonary and Critical Care Medicine CrossRef
  171. Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function
    Wei Zou et al, 2023, British J Pharmacology CrossRef
  172. Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
    Shanshan Chen et al, 2023, Front. Immunol. CrossRef
  173. Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
    Chang-Yao Chu et al, 2023, Sci Rep CrossRef
  174. Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network
    Mintao Xiao et al, 2023, Sci Rep CrossRef
  175. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
    Natalie I. Vokes et al, 2023, Ther Adv Med Oncol CrossRef
  176. Effects of Different Factors on the Efficacy of Anti PD-(L)1 Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer: An Observational, Retrospective Cohort Study
    Xiaoning Li et al, 2022, SSRN Journal CrossRef
  177. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
    Suna Zhou et al, 2023, Front. Immunol. CrossRef
  178. Mutual connected IL-6, EGFR and LIN28/Let7-related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy
    Junjun Li et al, 2023, Front. Oncol. CrossRef
  179. First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer
    So Yeon Kim et al, 2023, Hematology/Oncology Clinics of North America CrossRef
  180. Serum sPD-L1 levels are elevated in patients with viral diseases, bacterial sepsis or in patients with impaired renal function compared to healthy blood donors
    Lorin Loacker et al, 2023 CrossRef
  181. Regulation of PD-L1 Trafficking from Synthesis to Degradation
    Eyoel Yemanaberhan Lemma et al, 2023 CrossRef
  182. The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
    Qingyu Lin et al, 2023, Cancer Letters CrossRef
  183. Immune Resistance Mechanisms and the Road to Personalized Immunotherapy
    Miles Piper et al, 2023, American Society of Clinical Oncology Educational Book CrossRef
  184. Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1
    Yanzhen Chen et al, 2023, Front. Pharmacol. CrossRef
  185. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies
    Liming Liao et al, 2023, Front. Med. CrossRef
  186. Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
    Dan Yan, 2023, Biomedicines CrossRef
  187. The Complex Role of Thrombin in Cancer and Metastasis: Focus on Interactions with the Immune System
    Karolina Aleksandrowicz et al, 2023, Semin Thromb Hemost CrossRef
  188. The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells
    Zhuo Chen et al, 2023, Chinese Journal of Traumatology CrossRef
  189. Spontaneous regression of recurrent pulmonary large cell neuroendocrine carcinoma with alteration of PD‐L1 expression after surgical resection: A case report
    Green Hong et al, 2023, Thoracic Cancer CrossRef
  190. Strengthening the Combinational Immunotherapy from Modulating the Tumor Inflammatory Environment via Hypoxia‐Responsive Nanogels
    Wenhe Luo et al, 2023, Adv Healthcare Materials CrossRef
  191. Research Progress of EGFR-TKIs Resistance and PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer
    雅婷 温, 2024, ACM CrossRef
  192. Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Jiazheng Guo et al, 2024, RSC Med. Chem. CrossRef
  193. Tumor cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signaling in liver cancer
    Man Zhao et al, 2024, JHEP Reports CrossRef
  194. Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
    Zhongyu Jiao et al, 2023 CrossRef
  195. Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules
    Nikita Abramenko et al, 2024, Sci Rep CrossRef
  196. Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer
    T. Thamrongjirapat et al, 2024, BMC Cancer CrossRef
  197. From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer
    Yibin Zhou et al, 2024, Front. Immunol. CrossRef
  198. CD274 (PD-L1) negatively regulates M1 macrophage polarization in ALI/ARDS
    Nana Tang et al, 2024, Front. Immunol. CrossRef
  199. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
    Miaomiao Chen et al, 2024, International Immunopharmacology CrossRef
  200. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy
    Soon-Bin Kim et al, 2024, IJMS CrossRef
  201. Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies
    Firas Batrash et al, 2024, Cancers CrossRef
  202. TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma
    Linglu Wang et al, 2024, Cancer Letters CrossRef
  203. Iridium(III)-Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy
    Dongping Deng et al, 2024, J. Med. Chem. CrossRef
  204. Reversibly switchable fluorescent proteins: “the fair switch project”
    Riccardo Nifosì et al, 2024, Riv. Nuovo Cim. CrossRef
  205. CD47-mediated immune evasion in early-stage lung cancer progression
    Cheng-Hao Chuang et al, 2024, Biochemical and Biophysical Research Communications CrossRef
  206. Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics
    Minchen Cai et al, 2024, ABBS CrossRef
  207. NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis
    Fan Wu et al, 2024, Cell Death Discov. CrossRef
  208. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy
    Rui Han et al, 2024, IJN CrossRef
  209. The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review
    Amirhosein Sabaghian et al, 2024, J Cancer Metastasis Treat CrossRef
  210. NKX2‑1 copy number alterations are associated with oncogenic, immunological and prognostic remodeling in non‑small cell lung cancer
    Herdee Gloriane Luna et al, 2024, Oncol Lett CrossRef
  211. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
    Ping-Chih Hsu et al, 2018, Biomedicines CrossRef